Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

B-vitamin deficiencies in blood and urine (BVB)

Method of Measurement (Pre-analytical Tools)
Blood/Plasma
Other bodily fluids
Biomarker Measured
Genetic variation/DNA
Use
Diagnostic
Prognostic
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

Identify novel biomarkers in plasma and urine that can distinguish normal aging subjects with no cognitive impairment from those with mild, moderate or severe cognitive impairment associated with Alzheimer's disease.

Target Population/ Population Being Studied

Patients at least 40 years of age with MCI or mild, moderate, or severe AD

Length of Current Trial
6 months
Number of Trial Participants

220

Estimated Trial Completion
December 2022
What is Required from Patients

blood draw, mild discomfort, in clinic visits, urine sample

What is Required from the Health System

phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

Baylor Research Institute

“Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease (BVB).” ClinicalTrials.gov. Accessed  October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT03136679?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&rank=4